Hitting 52 Week High, Abbott Laboratories (NYSE:ABT) Settle At $74.38

ABT
ABT

Abbott Laboratories (NYSE:ABT)

February 13th, 2019
With markets going up Abbott Laboratories fell ($0.68) Wednesday which equals a 0.91% drop, closing at $74.38. Despite the drop in price it hit a new 52 week high of $75.27.

Abbott Laboratories is listed on the S&P 500 index, and was one of 165 stocks that slumped today. Weighted by market cap, ABT represents about 0.52% of the S&P 500.

Analysis results from 19 analysts indicates that Abbott Laboratories might go up somewhat (6.91%), while Finbox has calculated (with low uncertainty) a fair value price of $71.09.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending up. Energy saw the biggest increase of the day (1.29%), while Utilities saw the biggest drop (-0.31%). Industrials has seen the biggest year-to-date gain at 15.68%.

Energy saw the biggest turnaround from its 5-day performance of -1.99%, as it went up 1.29%. Utilities saw a turn around from its 5-day performance of 1.76% trading down -0.31%.

Sector Breakdown

  • Energy went up with a 1.29% change.
  • Industrials went up with a 0.63% change.
  • Consumer Discretionary went up with a 0.62% change.
  • Real Estate went up with a 0.58% change.
  • Consumer Staples went up with a 0.25% change.
  • Healthcare went up with a 0.25% change.
  • Financials went up with a 0.20% change.
  • Information Technology went up with a 0.14% change.
  • Materials went up with a 0.10% change.
  • Communication Services went down with a -0.10% change.
  • Utilities went down with a -0.31% change.

Abbott Laboratories Info

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

All amounts in USD unless otherwise indicated
ABT daily update

ABT daily update



Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.